Figure 4.
IFN-γ treatment of Fanca–/– and Fancg–/– recipients is sufficient to allow engraftment of syngeneic WT bone marrow cells. (A) CD45.1+ WT BM nucleated cells (107) were injected into the tail vein of Fanca–/– and Fancg–/– C57Bl/6 recipients that express the CD45.2 antigen. Recipients were pretreated with IFN-γ or vehicle control. The percentage of CD45.1+ cells in the peripheral blood was determined by fluorescence cytometry 6 months following transplantation. WT and Fancc–/– mice treated with PBS or IFN-γ were used as controls. Data points represent CD45.1+ chimerism of individual mice. Bars represent the mean CD45.1+ chimerism. *P < .001 comparing chimerism of Fanca–/– or Fancg–/– recipients treated with IFN-γ versus vehicle-treated Fanca–/– recipients and Fancg–/– recipients. Multilineage analysis of donor CD45.1 cells in representative (B) Fanca–/– and (C) Fancg–/– mice. The percentage of WT CD45.1+ lymphoid (CD3 and B220) and myeloid (Gr1 and Mac1) cells is shown in the top right corner of each fluorescence-activated cell sorter (FACS) profile.